Scan: When will Anduril IPO? — Before Jun 1, 2027

← Back to scans

When will Anduril IPO? — Before Jun 1, 2027

KXIPOANDURIL-27JUN01 · Economics · 2026-05-05

13%

Agent

23%

Market Price

-10.0%

Edge

60%

Confidence

Volume: 31,700

Spread: 13.0c

Days to resolution: 391

Markets in event: 16

Final Rationale

My independent estimate of 8.3% was driven by Anduril's $4B Series H at $60B in March 2026, Luckey's 'next few years' framing, and stated prerequisites (Arsenal-1 milestone in July 2026, profitability proof) — none of which suggest active IPO preparation. I PARTIALLY ACCEPT the critique on asymmetric treatment of Luckey's '2026 is possible' statement and the framing of crossover rounds (Snowflake/Databricks did raise large rounds pre-IPO), and I ACCEPT that resolution ambiguity around confidential S-1 filings warrants upward adjustment. I REJECT the math double-counting critique — sequential gating is appropriate when filing is a hard prerequisite. The market at 23% likely embeds signal I lack (banker engagement rumors, possible confidential filing); I move to 13% rather than fully to the market because the specific bearish evidence (fresh $4B raise, stated prerequisites) is concrete and recent, while the medium-reliability market with anomalous spread doesn't warrant full deference.

Price vs. prediction

How the market moved after the agent's call. Solid blue line is the actual market price; dashed line is the agent's static forecast at $t{=}0$.

$n = 58$ follow-ups

Re-scan Context

This market has been scanned before. Previous predictions:

Date	Predicted	Market Price	Confidence
2026-04-10	15%	17%	68%

1. Planner Opus · Fermi decomposition + tool plan

Tools chosen: web_search article_search kalshi_data kalshi_orderbook earnings_data wikipedia_lookup code_execution

Sub-questions (Fermi decomposition)

Has Anduril already filed for or confirmed an IPO as of May 2026? (w=0.25)
Will Anduril file for an IPO (S-1 or confidential filing) before December 2026? (w=0.35)
Will Anduril complete or confirm a public IPO between filing and June 1, 2027? (w=0.25)
Will defense-sector IPO market conditions remain favorable enough for Anduril to proceed with an IPO before June 2027? (w=0.15)

Planner reasoning

Anduril is a defense-tech unicorn (valued at ~$28B after 2024 funding) founded by Palmer Luckey. This question asks whether Anduril will confirm an IPO before June 1, 2027 — roughly 13 months from today. **Reference classes**: Defense-tech IPOs (Palantir went public via direct listing in 2020 after years of rumors; Shield AI has been rumored for IPO); high-valuation startup IPOs (historically ~40-50% of 'imminent' IPO candidates actually complete on stated timeline). Defense sector IPOs have been relatively more attractive given strong government contracts. **Causal mechanisms**: (1) Anduril's rapid growth and large contract wins (IVAS, Lattice) create IPO readiness; (2) Palmer Luckey's stated long-term vision may favor staying private; (3) Market conditions for tech/defense IPOs in 2026-2027; (4) Competition for capital from other defense unicorns; (5) No apparent need for capital forcing an IPO given recent funding rounds. **Key differentiators**: Unlike most tech companies, Anduril is heavily defense-focused with classified revenue streams that complicate public disclosures. The 13-month window is meaningful — if they file confidentially by early 2027, they could still complete by June. But the absence of any confirmed filing signals as of mid-2025 is a negative indicator. **Temporal analysis**: For YES to occur, Anduril would likely need to: (1) Make internal IPO decision by ~July 2026; (2) Confidentially file S-1 by ~October 2026; (3) Complete SEC review and roadshow by ~March-May 2027; (4) Price and list before June 1, 2027. Each step has meaningful uncertainty. The window is tight but not impossible. **Key unknowns**: Whether Anduril has already begun confidential preparations; management appetite for public markets; current defense spending environment under new administration.

2. Research Parallel tool calls · legacy v2

Tool	Status	Time	Items
web_search	OK	48.0s	-
article_search	OK	1.0s	-
kalshi_data	OK	2.1s	-
kalshi_orderbook	OK	0.2s	-
earnings_data	FAILED	0.5s	-
wikipedia_lookup	OK	2.1s	-
code_execution	OK	0.0s	-

Errors: earnings_data: None

3. Evidence Synthesis Sonnet · 17 items · legacy v2

#	Strength	Credibility	Direction	Source	Claim	Priced In
1	STRONG	78	↓ DOWN	web_search	As of May 2026, Anduril has not filed for or confirmed an IPO; Palmer Luckey said in October 2025 that an IPO is 'definitely' on the roadmap but 'in the next few years,' and the company is still private.	Yes
2	MODERATE	75	↓ DOWN	web_search	Executive Chairman Trae Stephens stated in June 2025 that Anduril is not on a 'rapid path' to IPO but is 'going through the processes required to prepare for doing something like that in the medium term.'	Yes
3	STRONG	82	↓ DOWN	web_search	In early March 2026, Anduril was nearly finished raising $4 billion at a $60 billion valuation (Series H), pushing total funding to over $10 billion — suggesting no immediate need for public capital.	Yes
4	MODERATE	60	↓ DOWN	kalshi_data	Kalshi prediction market prices Anduril IPO before June 1, 2027 at 23%, down 5% over 30 days, suggesting market participants view the IPO as unlikely in this window.	Yes
5	STRONG	76	↓ DOWN	web_search	Palmer Luckey has conditioned an IPO on proving Arsenal-1 (Ohio factory) works, with manufacturing expected to start July 2026 — suggesting any filing is unlikely before late 2026 at the earliest.	Yes
6	MODERATE	55	NEUTRAL	web_search	Analysts' consensus places an Anduril IPO as likely in 2026 or 2027, contingent on successful Ohio manufacturing expansion and favorable market conditions.	Yes
7	MODERATE	65	↑ UP	web_search	Andreessen Horowitz's Fund V (2016 vintage) will reach its 10-year anniversary in 2026, placing pressure on GPs to achieve a liquidity event for LPs by end of 2026.	Yes
8	MODERATE	72	NEUTRAL	web_search	Luckey suggested in October 2025 that 2026 is a possible year to go public, but also stressed wanting to be profitable before listing — no confidential filing has been confirmed.	Yes
9	STRONG	82	↓ DOWN	web_search	The $4B Series H at $60B valuation in March 2026 nearly doubles the prior round valuation ($30.5B) and reduces urgency for public market capital, making a near-term filing less likely.	Yes
10	STRONG	75	↓ DOWN	web_search	No IPO filing or public confirmation exists as of May 2026; for Anduril to complete an IPO before June 1, 2027, it would need to file confidentially by approximately February 2027 — leaving a very narrow window.	Yes
11	WEAK	35	NEUTRAL	code_execution	A base rate calculation suggests ~47% probability accounting only for time remaining (13 months), but this ignores company-specific conditions Luckey has stated must be met first.	No
12	MODERATE	72	↑ UP	article_search	Anduril's unmanned jet 'Fury' (YFQ-44A) completed its first test flight in October 2025, demonstrating product maturity that could support IPO readiness narratives.	Yes
13	MODERATE	70	↑ UP	article_search	IPO market showed strong performance mid-2025, with Circle, Chime, eToro, and Hinge Health all successfully pricing above range, suggesting a favorable IPO environment for high-profile listings.	Yes
14	MODERATE	80	↓ DOWN	article_search	A partial U.S. government shutdown began January 31, 2026, affecting many federal agencies — this could create uncertainty for defense contracts and IPO market conditions.	Yes
15	MODERATE	65	↑ UP	article_search	Broader defense-tech interest remains high, with drone/autonomous weapons receiving significant attention and investment from both government and private sectors through late 2025.	Yes
16	WEAK	55	NEUTRAL	article_search	IPO market recovery was described as a possible 'return to normalcy' rather than a boom, suggesting supportive but not euphoric conditions for large defense-tech listings.	Yes
17	MODERATE	58	↓ DOWN	web_search	Prediction market (Kalshi) data notes IPO timing is 'now more likely to occur later,' reflecting aggregate market assessment that near-term IPO is unlikely.	Yes

Information Gaps

No data on whether Anduril has begun confidential IPO preparations (engaged investment banks, auditors for SEC-compliant financials) as of May 2026
No information on Anduril's current profitability status — Luckey conditioned IPO on profitability but no revenue/profit data available
No information on the status of the Arsenal-1 Ohio factory as of May 2026 (was manufacturing actually started in July 2026 as planned?)
No information on whether Anduril secured any new major defense contracts in late 2025 or early 2026 that would strengthen IPO narrative
No data on current defense budget environment post-shutdown and its impact on Anduril's revenue pipeline
No information on whether any underwriters have been selected or engaged by Anduril
No clarity on how the resolution question handles 'confirms' vs. 'completes' an IPO — a confidential filing alone may not resolve YES

Key Uncertainties

Whether Arsenal-1 Ohio factory manufacturing milestone (July 2026) will be achieved on schedule, which Luckey has identified as a pre-IPO prerequisite
Whether Anduril is currently profitable or will achieve profitability before an IPO — a stated Luckey condition
Impact of government shutdown and defense budget uncertainty on Anduril's contract pipeline and IPO timing
Whether the $60B Series H round (March 2026) effectively removes near-term capital pressure and delays IPO beyond June 2027
How the prediction market resolves 'confirms' — whether a confidential S-1 filing counts or only a public announcement
Whether a16z's fund maturity pressure will force a liquidity event (IPO or secondary sale) before end of 2026
Market conditions in late 2026/early 2027 for large-cap defense-tech listings

Market Context

Price: 0.23 · 7d: +0.05 · 30d: -0.05
Volume: MODERATE · Depth: HIGH
Reliability: MEDIUM — moderate daily volume (528 contracts), high depth (12,491), but wide historical price range (9%-65%) suggests significant uncertainty among participants. The 30-day downtrend suggests recent negative updates. Orderbook spread of $0.98 is anomalous and may indicate data quality issue.

4. Independent Forecaster Opus · No market price · legacy v2 Did NOT see market price

Independent estimate: 8% (74% confidence)

base rate

78% conf

evidence driven

10%

72% conf

contrarian

72% conf

Spread

3pp

Low disagreement

sq1: Has Anduril already filed for or confirmed an IPO as of May 2026?

Strong direct evidence that as of May 2026, no IPO filing or confirmation exists. Luckey explicitly says 'next few years' and the recent $4B Series H at $60B valuation in March 2026 strongly signals continued private status. Base rate near 0; small residual for unconfirmed confidential filing.

sq2: Will Anduril file for an IPO before December 2026?

12%

Base rate for unicorn filing within ~7 months when no preparation announced: ~10-15%. Arsenal-1 manufacturing milestone is July 2026, and Luckey wants profitability proven first. The fresh $4B raise removes urgency. a16z fund maturity creates some pressure but secondaries can satisfy LPs without IPO. Final: ~12%.

sq3: Will Anduril complete or confirm a public IPO between filing and June 1, 2027?

10%

Conditional on filing happening in time, completion within window has historically ~60-70% probability. But this question is essentially asking the joint probability with the filing happening. Given filing must occur by ~Feb 2027 for completion by June 2027, and we have no evidence of preparation, probability is low. ~10%.

sq4: Will defense-sector IPO market conditions remain favorable?

60%

IPO market in 2025 was healthy, defense-tech enthusiasm remains, though government shutdown adds some uncertainty. Conditions are likely favorable enough but not exceptional. ~60%.

Show full reasoning trace

base rate: Historical base rate for a unicorn confirming an IPO within ~13 months when (a) no S-1 has been filed, (b) management has publicly stated 'medium term' / 'next few years', and (c) a massive private round just closed: roughly 5-10%.

evidence updates: DOWN: $4B Series H at $60B valuation in March 2026 is the strongest signal — companies don't typically raise $4B privately right before going public. DOWN: Luckey's October 2025 'next few years' language. DOWN: Stated profitability and Arsenal-1 prerequisites. UP (weak): a16z Fund V maturity pressure. UP (weak): Product maturity (Fury test flight). UP (weak): Generally favorable IPO market.

combination method: Weighted average gives ~16%, but the sub-questions are sequentially gating (filing must precede confirmation), so the effective probability is constrained by sq2 (~12%) and adjusted slightly downward for execution risk within the narrow window.

final: Final estimate ~8%. The combination of no filing evidence, fresh massive private capital raise, stated management timeline of 'next few years', and prerequisite conditions (Arsenal-1, profitability) makes a confirmed IPO before June 2027 unlikely though not impossible.

ensemble: {'ensemble_count': 3, 'perspectives': {'base_rate': {'p_yes': 0.08, 'confidence': 0.78}, 'evidence_driven': {'p_yes': 0.1, 'confidence': 0.72}, 'contrarian': {'p_yes': 0.07, 'confidence': 0.72}}, 'spread': 0.03, 'individual_p_yes': {'base_rate': 0.08, 'evidence_driven': 0.1, 'contrarian': 0.07}}

5. Devil's Advocate Sonnet · legacy v2 Market price revealed

Asymmetric Evidence Missing Info Reasoning Flaw Overconfidence

Challenges

The forecast may be conflating 'IPO completion' with 'IPO announcement/filing.' The question asks 'When will Anduril IPO?' resolving 'Before Jun 1, 2027' — but the resolution criteria for such questions on Kalshi/Polymarket often resolve YES on confirmed S-1 filing or public listing announcement, not just completion. The forecaster flags this in information gaps but doesn't adjust for it. If confidential filing counts, p_yes should be meaningfully higher.
The $4B Series H is treated as overwhelmingly bearish, but this logic is questionable. Large pre-IPO 'crossover' rounds (often led by mutual funds and crossover investors) are frequently a precursor to IPO within 12-18 months, not a substitute for one. Companies like Snowflake, Airbnb, and Databricks raised major rounds shortly before filing. The 'companies don't raise $4B privately right before going public' claim is empirically weak.
Sub-question combination has a math issue: sq3 is described as 'essentially the joint probability' but is then multiplied/constrained alongside sq2, which double-counts the filing requirement. The proper decomposition is P(file by ~Feb 2027) × P(complete | filed in time), not three sequentially gating probabilities.
The forecaster dismisses Luckey's October 2025 statement that '2026 is a possible year to go public' while heavily weighting the 'next few years' phrasing. These are from the same speaker and the former is more specific to the resolution window. Asymmetric treatment of the same source.
Confidence of 0.74 seems high given multiple acknowledged information gaps (no data on banker engagement, profitability, Arsenal-1 status, confidential filing status). A 391-day horizon with these gaps warrants wider uncertainty.
The market at 23% with moderate volume and high orderbook depth, trending only modestly down, represents aggregated information that may include knowledge of banker engagements or filing prep not visible to the forecaster. The 14.7% divergence isn't dispositive but the forecaster's confidence that they're right and the market is wrong isn't well-justified given the information gaps.

Suggested adjustment: +5pp

Adjust upward modestly (~+5pp to ~13%) due to: (1) asymmetric treatment of Luckey's own statements (ignoring '2026 is possible' in favor of 'next few years'), (2) questionable framing of the Series H as anti-IPO when crossover rounds often precede IPOs, (3) potential resolution ambiguity where confidential S-1 filing might resolve YES, and (4) overconfidence given multiple acknowledged information gaps about banker engagement and filing prep. This is not adjustment toward the market, but correction of specific reasoning flaws.

Market comparison: Forecaster: 8.3%, Market: 23%. The divergence is large but not unjustified — the forecaster has identified genuinely bearish specific evidence (Series H, Luckey's stated prerequisites). However, some of that evidence is interpreted with anti-IPO bias, and key information gaps (confidential filing status, banker engagement) mean the market's higher price could reflect signal the forecaster lacks. A forecast in the 12-15% range would better reflect both the bearish evidence and the residual uncertainty.

6. Aggregator Opus · final calibrated forecast

13% (60% confidence)

7. Entry Decision Opus Trader

Side

Position Size

$900

Contracts

1000

Trader Confidence

60%

Trade Rationale

Edge is -10% (forecast 13% vs market 23%), driven by concrete recent evidence: Anduril's $4B Series H at $60B in March 2026, stated prerequisites (Arsenal-1 milestone, profitability proof), and Luckey's 'next few years' framing. Forecaster confidence is moderate at 0.60, and the Devil's Advocate flagged multiple concerns (asymmetric evidence, missing info on banker engagement) which warrant some caution. I also already hold a correlated NO position on 'Will Citigroup take SpaceX public before Jan 1, 2028?' — both are bets against near-term defense/aerospace IPOs, so I'm sizing down slightly to manage thematic concentration. The 391-day horizon also adds tail risk if a confidential S-1 surfaces.

Allocation Logic

Below baseline ($900) because of (a) moderate forecaster confidence with critic flags suggesting +0.05 adjustment, and (b) correlation with existing SpaceX-IPO NO position. The 10% edge justifies a real position but not a large one given missing info on banker activity.

Entry price: $0.90

Current: $0.83

Status: OPEN

P&L: -$70.00